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Abstract. Dengue is the most significant arthropod-borne viral infection of humans. Persons infected with dengue
viruses (DENV) have subclinical or clinically apparent infections ranging from undifferentiated fever to dengue hemor-
rhagic fever/shock syndrome. Although recent studies estimated that the Indian subcontinent has the greatest burden of
DENV infection and disease worldwide, we do not have reliable, population-based estimates of the incidence of infection
and disease in this region. The goal of this study was to follow-up a cohort of 800 children living in a heavily urbanized
area of Colombo, Sri Lanka to obtain accurate estimates of the incidence of DENV infection and disease. Annual blood
samples were obtained from all children to estimate dengue seroprevalence at enrollment and to identify children exposed
to new DENV infections during the study year. Blood was also obtained from any child in whom fever developed over
the course of the study year to identify clinically apparent DENV infections. At enrollment, dengue seroprevalence was
53.07%, which indicated high transmission in this population. Over the study year, the incidence of DENV infection and
disease were 8.39 (95% confidence interval = 6.56–10.53) and 3.38 (95% confidence interval = 2.24–4.88), respectively,
per 100 children per year. The ratio of clinically inapparent to apparent infections was 1.48. These results will be useful
for obtaining more accurate estimates of the burden of dengue in the region and for making decisions about testing and
introduction of vaccines.
INTRODUCTION
Dengue is caused by four related mosquito-borne dengue
viruses (DENV1–4), which are endemic to many tropical and
subtropical regions of the world. Most persons infected with
DENV are asymptomatic or show development of a febrile
illness known as dengue fever, but disease can be more severe
and progress to dengue hemorrhagic fever and dengue shock
syndrome (DHF/DSS). Infection with one DENV serotype
confers protective immunity to future infections with that sero-
type only and these persons are susceptible to secondary infec-
tions with heterologous serotypes.1 Persons with secondary
DENV infections are at a greater risk of DHF/DSS than
persons having their first infection.2,3
Globally, an estimated four billion persons are at risk for
DENV infection, and there are an estimated 390 million
annual DENV infections and 96 million dengue cases.4 From
prospective community and school-based cohort studies, it
has been possible to obtain estimates for the incidence of
DENV infection and disease for sites in southeast Asia5–10
and Latin America.11–13 Although dengue is emerging in the
Indian subcontinent and is considered a major health issue,
we do not have estimates of the true burden of DENV infec-
tion and disease in this region.
Dengue was first reported in Sri Lanka in the 1960s.14
Studies conducted during 1980–1984 showed a DENV sero-
prevalence of 50% among school children and an annual
seroconversion rate of 10–15% among 5–7-year-old school
children in Colombo, the capital of Sri Lanka.15,16 More
recently, analysis of age-stratified seroprevalence data indi-
cated that the annual seroconversion rate among children
< 12 years of age in Colombo is approximately 14%.16 In the
past, most dengue cases have been reported from the
Colombo district and other neighboring districts in the heavily
urbanized southwestern region of the country. However, over
the past 10–15 years, dengue has been reported from nearly
all districts of the island, and over the past two decades, the
number of reported DF and DHF cases has increased by more
than 10-fold.17 This increase in cases has been attributed to
introduction of new genotypes of DENV, as well the expansion
of the range of the virus on the island.17–19 In many ways, the
changing epidemiology of dengue in Sri Lanka mirrors events
in other parts of the subcontinent including India, which
has also documented large increases in cases and appearance
of new virus strains.20,21 We conducted a population-based
study to determine the incidence of symptomatic and asymp-
tomatic DENV infection among children living in Colombo,
Sri Lanka, an urban setting of the Indian subcontinent.
MATERIALS AND METHODS
Ethical approval for study. Ethical approval for this
research was obtained from the Ethical Review Committee
of the Faculty of Medicine, University of Colombo, Sri Lanka,
and the Institutional Research Board of the International
Vaccine Institute, Seoul, South Korea. Only children whose
parents or legal guardians provided written informed consent
were enrolled in the study.
Study site. The study was conducted in the city of Colombo,
the commercial capital of Sri Lanka, which has a population
of 647,100 and is the most densely populated area in the
country; there are 17,353 persons/km2.22 The city is divided
into 47 municipal wards. Ward 33 was selected for the study
because of its stable population, which reflects the socio-
economic status and demographics of the entire municipal
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area. Dengue is endemic to this ward, and the catchment
population seeking healthcare in the tertiary care institution
situated within its boundaries (Figure 1).
Study population. A prospective cohort study was con-
ducted during November 2008–January 2010. The protocol
for the study is described in detail elsewhere.23 In brief, a
house-to-house census was conducted by research assistants
to determine the size and obtain sociodemographic informa-
tion and health-seeking patterns of the permanent resident
population of children £ 12 years of age. A representative
sample of 800 children £ 12 years of age was recruited for the
current study. The sample size calculation was based on the
ability to detect an annual incidence of dengue of 10% with
an absolute precision of 3%. The estimated sample size was
then inflated by 30% to allow for possible loss to follow-up
during the study period. All children were enrolled in the study
after written informed consent was obtained from parents/
legal guardians and consent from children > 7 years of age.
Each participating household was given a thermometer and
each child was given an identification card with a unique
study number. A febrile illness was defined as a temperature
³ 38°C lasting £ 7 days in any child in the study cohort docu-
mented by a parent, research assistant, or health care profes-
sional. After assessment and treatment by a designated
physician, the research assistants interviewed the patient and
parent by using a standard case investigation form.
Sample collection. Blood samples were obtained from all
children at enrollment (during November 2008–January 2009)
and one year after enrollment (during November 2009–January
2010) by finger prick and stored as blood spots on protein saver
cards (Whatman, Piscataway, NJ and Id Biological Systems,
Greeneville, SC).24,25 From children with a documented fever,
whole blood was collected by venipuncture and placed in
tubes containing EDTA. Some of the whole blood was used
to prepare dried blood spots for serologic testing. The remain-
ing blood was centrifuged and the plasma used for molecular
diagnostic testing. Ten or more days after recovery from
fever, convalescent-phase samples were collected by finger
prick and stored as blood spots on protein saver cards.
DENV strains used for laboratory assays. The World Health
Organization reference DENV strains (i.e., DENV1 West
Pac 74, DENV2 S-16803, DENV3 CH54389, and DENV4
TVP-360) were used for preparing antigen and infectious
stocks for serologic assays. These reference viruses were ini-
tially obtained from Dr. Robert Putnak (Walter Reed Army
Institute of Research, Silver Spring, MD). Infectious stocks of
Figure 1. Location of study site (Ward 33) in relation to the Colombo Municipal Council (MC) and Colombo District, Colombo, Sri Lanka.
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virus were prepared by using the C6/36 mosquito cell line, and
dengue antigens were harvested from Vero cells as described.26
Molecular detection of DENV. Plasma obtained during
the acute phase of the febrile illness was tested by reverse
transcription–polymerase chain reaction (RT-PCR) to detect
and serotype DENVs as described.17
Detection of IgM and IgG against DENV in dried
blood spots. Antibodies were eluted from dried blood spots
by submerging the filter paper in phosphate-buffered saline
and incubating at 37 °C for 2.5 hours. The final volume of the
eluted antibody was adjusted to obtain a 1:50 or 1:100 dilu-
tion of the original blood volume applied to the filter paper.
A recent report validated the use of dried blood spots for
dengue serologic analysis.27
We performed dengue IgM capture enzyme-linked immu-
nosorbent assay (ELISA) as described,28 except that mono-
clonal antibody (MAb) 4G2 against flavivirus, followed by
enzyme-conjugated goat anti-mouse IgG to detect captured
DENV antigen. In brief, 96-well plates were coated (over-
night at 4°C) with 100 mL/well (1 ng/mL) of goat anti-human
IgM (Sigma, St. Louis, MO) at a concentration of 0.1 mol/L in
carbonate buffer, pH 9.6. Plates were washed three times in
Tris-buffered saline containing 0.2% Tween 20 (TBST) and
blocked with 200 mL/well of 1 +Tris-buffered saline containing
0.05% Tween 20 and 3% nonfat dry milk. Paired serum sam-
ples were tested on the same plate. Diluted serum (1:50) was
loaded in duplicate and incubated (37°C for 1 hour) to capture
IgM. Unbound antibody was washed, and wells were succes-
sively incubated with DENV antigen (mixture of serotypes
DEN1–4), mouse anti-flavivirus 4G2 MAb, and human-
absorbed alkaline phosphatase (AP)–conjugated goat anti-
mouse IgG (Sigma). Optical density (OD) was measured at
405 nm after final incubation with AP substrate.
Dengue IgG ELISA was performed as described.29 Plates
were coated overnight (4°C) with 100 mL/well of mouse anti-
flavivirus 4G2 MAb at a concentration of 0.1 mol/L in car-
bonate buffer, pH 9.6, and then washed three times in TBST.
Plates were then blocked with standard diluents and succes-
sively incubated (37°C for 1 hour) with DEN1–4 antigen,
diluted serum (1:100) in duplicate wells, and AP-conjugated
goat anti-human IgG (Fc portion). Three washings with TBST
were conducted between incubations. Plates were read at
405 nm after a final incubation with AP substrate (15 minutes
at room temperature in the dark).
Measurement of DENV neutralizing antibodies. The pres-
ence of DENV neutralizing antibody was determined by
using a flow cytometry–based neutralization assay with U937
monocytic cells stably transfected with dendritic cell-specific
intercellular adhesion molecule-3-grabbing non-integrin as
described.30 This flow cytometery–based neutralization test
has comparable specificity to the conventional dengue plaque-
reduction neutralization test and does not detect antibodies
against Japanese encephalitis virus (Broadwater A, de Silva
AM, unpublished data).30 Blood samples were serially diluted
(four-fold dilutions starting at 1:40 and ending at 1:10,240) and
the serum dilution that neutralized 50% of the viruses was
calculated by nonlinear, dose-response regression analysis with
Prism 4.0 software (GraphPad Software, Inc., San Diego, CA).
Determination of dengue serostatus at study enrollment.
DENV serostatus (DENV naive or immune) at enrollment
was determined by using a dengue IgG immunoassay. An
OD value ³ 0.3 were considered dengue antibody positive.
During the study period, primary infections were defined as
dengue-naive children at enrollment who had had an infec-
tion. Secondary infections were defined as dengue-immune
children at enrollment who had had an infection.
Laboratory criteria for diagnosis of new DENV infections.
A laboratory-confirmed clinically apparent dengue case was
defined as a child who had a febrile illness and showed
positive results in at least two of the three diagnostic assays
(PCR, increasing levels of IgM and/or IgG in paired acute-
phase and convalescent-phase blood samples). In the few
cases in which there was only an acute-phase blood sample,
the diagnosis was based on RT-PCR testing only. To detect
clinically inapparent infections, paired baseline and end-of-
year blood samples from all children were tested by IgG
immunoassay. Dengue-naive children at enrollment (391 chil-
dren) who seroconverted over the study year (baseline
sample seronegative and end-of-year sample seropositive
[³ 0.3 OD units]) were classified as primary infections. Clas-
sification of these cases as primary infections was confirmed
by neutralization testing of selected samples. The DENV-
immune children at enrollment (441 children) who had
increasing levels of IgG against DENV by the end of the year
(³ 0.1 OD units) were initially classified as secondary infec-
tions. However, neutralization testing indicated that when
samples were collected 12 months apart, the IgG ELISA had
poor specificity for detecting secondary infections (Corbett
KS and others, unpublished data). Therefore, we tested paired
baseline and end-of-year samples from all children who were
dengue immune at enrollment for the presence of neutralizing
antibodies against each of the four serotypes.
To establish criteria for defining secondary infections by
using paired samples obtained 12 months apart, we used a test
set of eight symptomatic secondary cases (detected by PCR
and serologic analysis performed on samples collected within
one month of acute infection). Only half (4 of 8) of the cases
had a ³ 4-fold increase, and all (8/8) of the cases had a ³ 2-fold
increase in neutralizing antibody levels when paired baseline
and end-of-year samples from these children were tested.
Therefore, children who had ³ 2 fold increases in levels of
neutralizing antibodies to one or more serotypes by the end
of the year were designated as secondary infections. Samples
were tested at least twice and only paired samples that
displayed a reproducible two-fold increase were included as
new secondary infections. Inapparent cases were defined as
children who had not been identified as a clinical dengue case
over the study year but still seroconverted by IgG immunoassay
(primary infections) or had increasing levels of neutralizing
antibodies (secondary infections) by the end of the study year.
RESULTS
During November 2008–February 2009, a total of 800 chil-
dren between 0–12 years of age were enrolled in the study
from ward 33 (Figure 1); these children were representative
of the age and demographic distribution of the 2,527 children
known to be permanent resident of the ward. Only one child
was lost to follow-up during the study period.
The dengue seroprevalence at enrollment was determined
by testing all children by ELISA for IgG against DENV
(Table 1). To confirm that IgG seropositivity was caused by
dengue infection and not exposure to related Japanese enceph-
alitis virus, which is also present in Sri Lanka, all IgG-positive
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samples were tested for DENV-neutralizing antibodies. Most
(96%) of IgG-positive serum samples also neutralized DENV,
indicating that in this population the results of the IgG ELISA
reflected dengue seroprevalence. The overall dengue sero-
prevalence was 53% at enrollment (Table 1). The age specific
seroprevalence steadily increased with age from a low of 22%
in the youngest (< 1 year) age group to a high of 74.26% in the
oldest (10–12 years) age group (Table 1).
A total of 681 fever episodes were detected among the
799 children, indicating that on average each child reported
0.9 fever episodes over one person-year of follow-up (Table 2).
Dengue was laboratory confirmed for 3.9% (27 of 681) of the
fever episodes (Table 2); no child had more than one episode
of dengue fever over the course of the study. Therefore, the
incidence of clinically apparent dengue in the cohort was
3.38 cases/100 children/year (Table 2). When combined with
the clinically inapparent infections, the total incidence of DENV
infection was 8.39 cases/100 children (Table 2). The highest
incidence of infection and disease was in children 1–3 years of
age. The overall ratio of inapparent to apparent infections
was 1.48. We used a two-fold instead of a four-fold increase
in neutralizing antibody levels to identify new secondary
infections because a four-fold increase had poor sensitivity
for paired samples collected 12 months apart. It is possible
that the two-fold increase reduces specificity and leads to a
modest overestimation of true incidence.
Of the 67 new apparent and inapparent DENV infections,
35 were primary infections and 32 were secondary infections
(Table 3). As might be expected, the ratio of primary to
secondary infections decreased with age from 3 in the youn-
gest (< 1 year) age group to 0.75 in the oldest (10–12 years)
age group. The ratios of inapparent to apparent infections
were not statistically significantly different (P > 0.1) between
primary and secondary infections (Table 3).
The prevalence of each DENV serotype during the study
year was estimated by identifying the serotypes responsible
for primary infections (Supplemental Table 1). DENV2 was
the most common serotype (49%) followed by DENV3 (27%),
DENV1 (23%), and DENV4 (3%). The number of persons
with monospecific neutralizing antibodies to each serotype at
enrollment into the study was used to estimate the prevalence
of each serotype in this population before the start of our study
(Supplemental Table 1). This analysis showed that DENV2
(43%) and DENV3 (29%) were more common than DENV1
(9%) and DENV4 (12%) in the period preceding the study.
DISCUSSION
Over the past two decades, dengue has emerged as a major
health problem in the Indian subcontinent.20,21 Dengue epi-
demics in the region have been linked to more intense trans-
mission, expansion of the range of the virus, and introduction
of new strains.17–21 Most estimates of dengue incidence in the
region are based on hospital-based studies and nationally
reported cases, which grossly underestimate the true burden
of disease and infection.31 We followed a cohort of 799 chil-
dren in Colombo, Sri Lanka, and estimated the incidence of
infection and disease to be 8.39 and 3.38 cases/100 children,
respectively. The ratio of clinically inapparent to apparent
infections was 1.48, which indicated that for every apparent
infection there were approximately 1.5 inapparent infections
in children. This high intensity of transmission was also sup-
ported by the seroprevalence data, which showed a gradually
increasing prevalence with age that ranged from 22% in the
youngest age group to 74% in the oldest age group. The
four DENV serotypes were circulating in this population
before and during our study; serotypes 2 and 3 were more
prevalent than serotypes 1 and 4 (Supplemental Table 1).
Our study establishes a rigorously measured, accurate burden
of dengue infection and disease among children living in
an urban area of Sri Lanka.
Recently, we used dengue seroprevalence data from this
cohort to model the rate of primary infections in dengue-
naive children.16 Using a catalytic model, we estimated
the incidence of primary infection to be 14.1% per year
Table 1











< 1 51 12 11 21.57
1–3 196 71 67 34.18
4–6 191 105 100 52.36
7–9 225 150 145 64.44
10–12 136 103 101 74.26
Total 799 441 424 53.07
*Dengue seroprevalence at the beginning of study (baseline) was determined by screening
all serum samples by dengue IgG enzyme-linked immunosorbent assay (ELISA) and then
testing the positive samples by dengue neutralization test.
Table 2
Age-specific fever episodes and incidence of dengue infection and illness in children, Sri Lanka*
Age (years) No. children
Fever episodes New dengue infections
Incidence of infection per 100 children Incidence of disease per 100 childrenTotal Mean/child Total Inapparent Apparent
< 1 51 31 0.6 1 0 1 1.96 (0.05–10.45) 1.96 (0.05–10.45)
1–3 196 252 1.3 27 15 12 13.78 (9.28–19.41) 6.12 (3.20–10.45)
4–6 191 174 0.9 13 11 2 6.81 (3.67–11.36) 1.05 (0.13–3.73)
7–9 225 137 0.6 15 6 9 6.67 (3.78–10.76) 4.00 (1.85–7.46)
10–12 136 87 0.6 11 8 3 8.09 (3.25–16.03) 2.21 (0.46–6.31)
Total 799 681 0.9 67 40 27 8.39 (6.56–10.53) 3.38 (2.24–4.88)
*Values in parentheses are 95% confidence intervals. Clinically apparent dengue infections were diagnosed by performing paired serologic analysis and polymerase chain reaction on acute-
phase and convalescent-phase serum samples obtained from febrile children. Total dengue infections over the study year were detected by testing paired baseline and end of year samples by IgG
enzyme-linked immunosorbent assay and neutralization test. Children who were infected but not identified as having apparent cases were designated as having inapparent cases.
Table 3




Inapparent Apparent Inapparent:apparent ratio
Primary, 35 20 15 1.33
Secondary, 32 20 12 1.67
Total, 67 40 27 1.48
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(95% confidence interval [CI] = 12.7–15.6%), which is
higher than the incidence of 8.39% (95% CI = 6.56–10.53%)
observed for total infections (primary and secondary infec-
tions). A more legitimate comparison would be to compare
the model based estimate for primary infections with the inci-
dence of primary infections in our cohort. The incidence
of primary infection noted in the current study was 9.8%
(95% CI = 6.80–12.80%), which is closer to the model-based
estimate of 14.1% per year (95% CI = 12.7–15.6%). A previ-
ous study of school children in Colombo over a five-year
period during 1980–1985 estimated the incidence of new
infections to range between 10.78 and 18.54 cases/100 children
in different years.15 Collectively, these findings demonstrate
intense transmission of dengue among children in Colombo.
Our current estimate for disease (3.38 cases/100 children
< 12 years of age) is 14-fold higher than the reported national
incidence of the disease (0.23/100 persons) among persons
< 15 years of age in 2010 in Sri Lanka, which is based on the
passive national surveillance system (Epidemiology Unit, Min-
istry of Health). Based on national surveillance for 2010, the
disease estimates for children < 15 years of age in the Colombo
district and the Colombo Municipality (study area) (Figure 1)
were 0.64 and 1.61 cases/100 persons, respectively. Thus, as
expected, the passive national program underreports the true
burden of disease in Sri Lanka. Recent studies in Southeast
Asia have estimated expansion factors of 8.9 and 9.6 when
comparing national data with true disease incidence for
Thailand and Cambodia, respectively.7,32 Moreover, a recent
study of the global burden of dengue estimated that there are
three times as many infections and dengue cases compared
with cases reported to the World Health Organization.4
For most regions in the world with endemic dengue trans-
mission, we do not have accurate estimates of infection and
disease because of the cost and infrastructure required to
conduct cohort studies. The most comprehensive cohort
studies on dengue in Southeast Asia have been conducted in
Thailand where the incidence of infection has ranged between
2% and 15% depending on the year and location of the
study.5,6,8,33,34 Studies in Puerto Rico, Nicaragua, and Peru
have documented incidences that range between 1.34% and
12% depending on the year and location.11,12 Thus, the inten-
sity of dengue transmission among children in Colombo
(8.14%) is similar to transmission documented in other cohort
studies conducted in Southeast Asia and Latin America. The
ratio of inapparent to apparent infections has also been esti-
mated in different regions of the world. In southeast Asia, the
ratio has ranged from 3:1 to 1:1, whereas in Latin America the
ratio has ranged from 3:1 to 18:1, indicating that infections in
Southeast Asia5,6,8 are more likely to lead to clinically appar-
ent cases than infections in Latin America.11,12 The data we
report indicate that the situation in Colombo Sri Lanka with a
ratio of 1.5:1 is more similar to the situation in Southeast Asia.
The current study was not designed to test hypotheses about
risk factors for DHF/DSS because our cohort of 799 children
is too small to detect significant numbers of DHF/DSS cases.
We did not observe any significant differences in the ratio of
inapparent to apparent cases between primary and secondary
cases. However, it is premature to conclude from these data
that risk of developing a clinically apparent infection is the
same in primary and secondary cases because the study was
only powered to detect a large difference in risk after primary
and secondary infection. Other studies have documented that
children exposed to primary and secondary infections have a
similar risk of developing clinically apparent infections.6
It is well documented that the incidence of infection and
disease can vary from year to year and our data were collected
over a single year only. Our study was confined to a relatively
small area and our results may not be generalizable to children
in other parts of the city and country. Thus, studies such as this
have to be conducted in other parts of the country over a
longer period to understand how the incidence of infection
and disease vary by location and over time. Dengue vaccines
are currently being tested in different regions of the world.35 It
is important that trials also be conducted in the Indian subcon-
tinent given the heavy burden of disease and the distinct strains
of DENV circulating in the region. The results of the current
study will be useful for designing vaccine trials in southern Asia
and for making decisions about how best to introduce vaccines.
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